Brokers Issue Forecasts for IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($2.60) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.45) per share.

Several other equities analysts have also recently issued reports on the company. Stephens assumed coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They issued an “overweight” rating and a $51.00 price target on the stock. Leerink Partnrs lowered IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Oppenheimer reaffirmed an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Wedbush reissued an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Leerink Partners cut shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $53.67.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $23.15 on Wednesday. The company’s fifty day moving average is $25.95 and its two-hundred day moving average is $32.15. IDEAYA Biosciences has a 1 year low of $22.10 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter in the previous year, the business earned ($0.46) EPS.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of IDYA. State Street Corp raised its holdings in IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares during the last quarter. Scientech Research LLC increased its position in shares of IDEAYA Biosciences by 362.3% in the second quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after buying an additional 21,714 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in shares of IDEAYA Biosciences by 34.4% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 884,538 shares of the company’s stock worth $31,056,000 after buying an additional 226,514 shares during the last quarter. Barclays PLC boosted its position in shares of IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock worth $5,739,000 after buying an additional 118,438 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in IDEAYA Biosciences by 24.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 104,553 shares of the company’s stock valued at $3,671,000 after acquiring an additional 20,607 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.